The stock price of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has dropped by -4.21 compared to previous close of 1091.98. Despite this, the company has seen a fall of -8.79% in its stock price over the last five trading days. benzinga.com reported 2024-09-24 that Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.‘s REGN effort to prevent the sale of Amgen Inc‘s AMGN Eylea biosimilar.
Is It Worth Investing in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Right Now?
The price-to-earnings ratio for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is 27.70x, which is above its average ratio. Moreover, the 36-month beta value for REGN is 0.12. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 7 as “overweight,” 12 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for REGN is 106.30M and currently, short sellers hold a 1.98% of that float. On September 25, 2024, REGN’s average trading volume was 466.22K shares.
REGN’s Market Performance
REGN stock saw a decrease of -8.79% in the past week, with a monthly decline of -12.77% and a quarterly a decrease of -2.35%. The volatility ratio for the week is 3.36%, and the volatility levels for the last 30 days are 2.29% for Regeneron Pharmaceuticals, Inc. (REGN). The simple moving average for the past 20 days is -9.68% for REGN’s stock, with a 4.78% simple moving average for the past 200 days.
Analysts’ Opinion of REGN
Bernstein, on the other hand, stated in their research note that they expect to see REGN reach a price target of $1125. The rating they have provided for REGN stocks is “Outperform” according to the report published on March 12th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to REGN, setting the target price at $1076 in the report published on January 12th of the current year.
REGN Trading at -7.43% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.64% of loss for the given period.
Volatility was left at 2.29%, however, over the last 30 days, the volatility rate increased by 3.36%, as shares sank -12.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.34% lower at present.
During the last 5 trading sessions, REGN fell by -8.79%, which changed the moving average for the period of 200-days by +25.15% in comparison to the 20-day moving average, which settled at $1,150.36. In addition, Regeneron Pharmaceuticals, Inc. saw 19.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $1178.73 back on Sep 03 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc., valued at $1,178,730 using the latest closing price.
RYAN ARTHUR F, the Director of Regeneron Pharmaceuticals, Inc., sale 100 shares at $1178.68 during a trade that took place back on Sep 03 ’24, which means that RYAN ARTHUR F is holding 17,682 shares at $117,868 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.86 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc. stands at 0.32. The total capital return value is set at 0.12. Equity return is now at value 16.55, with 12.95 for asset returns.
Based on Regeneron Pharmaceuticals, Inc. (REGN), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 2.05. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 125.35.
Currently, EBITDA for the company is 5.13 billion with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 8.46. The receivables turnover for the company is 2.36for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.44.
Conclusion
To wrap up, the performance of Regeneron Pharmaceuticals, Inc. (REGN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
